Loading...

ZURA ZURA BIO LTD Name Changes 8-K Filing

ZR B

ZR

ZURA BIO LTD

(ZURA)

2026 8-K

Director Resignation

Financial Results Update

Management Changes

Financial Results Announced

Corporate Presentation Update

Press Release Issued

Funding Announcement

Corporate Presentation Update

Corporate Update

Agreement Termination

Director Resignation

Q3 Financial Results

Management Change

Severance Plan Update

Corporate Presentation Update

Press Release Issued

Financial Results Released

Financial Statements

Share Agreements

Corporate Presentation

Financial Results

Regulation FD Disclosure

Corporate Presentation

Regulation FD Disclosure

Regulation FD Disclosure

Regulation FD Disclosure

Q3 Financial Results

Regulation FD Disclosure

Annual Meeting Results

Management Change

Corporate Presentation

Regulation FD Disclosure

Share Surrender

Corporate Presentation

Q2 Financial Results

Warrant Exchange

Exchange Offer and Consent ...

Departure of CEO and Appoin...

Exchange Offer and Consent ...

Appointment, Salary Increase

Financial Results

Private Placement

Regulation FD Disclosure

Financial Results and CEO T...

Investor Conferences

Changes in Certifying Accou...

Investor Presentation

Departure of Directors and ...

Appointment of Executive Vi...

Regulation FD Disclosure

Regulation FD Disclosure

Investor Presentation

Appointment of Director

Regulation FD Disclosure

Earnings Reports

Investor Presentation

Investor Presentation

Equity Securities Sale

Shareholder Meeting Approval

Private Placement

Press Release and Investor ...

Regulation FD Disclosure

Service Agreements

Resignation of Officer

Business Combination

Press Release and Forward P...

Regulation FD Disclosure

Business Combination Approval

Listing Transfer

Amendment to Forward Purcha...

Business Combination Announ...

Business Combination Agreem...

External Links:

On January 12, 2026, Zura Bio Ltd announced corporate and clinical trial updates, including timelines for data readouts from ongoing Phase 2 studies of tibulizumab. The company also provided insights into its cash runway and outlook for 2026.

AI Assistant

ZURA BIO LTD

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.